Experts detail the exploration of minimal residual disease and the integration of ctDNA into lymphoma management.
David A. Russler-Germain, MD, PhD, discusses how data with MRD and ctDNA testing in solid tumors inform their potential application in hematologic malignancies.
ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.
Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.
Sarah Rutherford, MD, discusses emerging roles for ctDNA and MRD in lymphoma, highlighting surveillance value, personalized assays, and evolving adoption.
